Disproportionality analysis for identification of drug safety signals in a database shared by the Norwegian network of drug information centres (RELIS)
The Norwegian network of drug information centres (RELIS) has developed a full-text, searchable question (Q)-answering (A) database with nearly 50,000 Q/A pairs. The RELIS database is used to document decision support in complex clinical cases provided by clinical pharmacologists and pharmacists with written responses within a requested time frame [1, 2]. Selected Q/A pairs are published online in Norwegian on www.relis.no as open access and are freely available to healthcare professionals. Answers considered as not having any general interest, or questions that are so specific there is a risk the patient can be identified, are only available for the RELIS staff. All Q/A pairs are indexed by the staff, and searchable through selection of drugs (e.g., generic, ATC-code), categories (e.g., adverse effects, interactions), and text words (e.g., dependency, misuse). The search function used by the staff includes Boolean operators (e.g., AND/OR/NOT) to allow combined searches [1, 2].
KeywordsDatabase Decision support Disproportionality analysis Drug information centre Drug safety
Authors’ individual contributions
The manuscript was drafted by the idea of Jan Schjøtt, who is also responsible for the statistics. Charlotte L. Stokes has contributed in writing, reference search, and submission.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Schjøtt J, Reppe LA, Roland PD,Westergren T (2012) A question-answer pair (QAP) database integrated with websites to answer complex questions submitted to the Regional Medicines Information and Pharmacovigilance Centres in Norway (RELIS): a descriptive study. BMJ Open 2:e000642Google Scholar
- 2.Schjøtt J. (2017) Benefits of a national network of drug information centres: RELIS. Eur J Clin Pharmacol. 73(1):125–126.Google Scholar
- 4.Ventola CL (2018) Big data and pharmacovigilance: data mining for adverse drug events and interactions. P T 43(6):340–351Google Scholar
- 5.Anon (2016) Quetiapine: misuse and abuse. Prescrire Int 25(169):68Google Scholar
- 6.Chiappini S, Schifano F (2018) Is there a potential of misuse for quetiapine?: literature review and analysis of the European Medicines Agency/European Medicines Agency adverse drug reactions’ database. J Clin Psychopharmacol 38(1):72–79Google Scholar
- 11.Driot D, Jouanjus E, Oustric S, Dupouy J, Lapeyre-Mestre M (2019) Patterns of gabapentin and pregabalin use and misuse: Results of a population-based cohort study in France. Br J Clin Pharmacol. https://doi.org/10.1111/bcp.13892
- 12.Böhm R. Primer on disproportionality analysis. Version: 2018-10-16. http://openvigil.sourceforge.net/doc/DPA.pdf. Accessed 10th April 2019